Please login to the form below

Not currently logged in
Email:
Password:

Verzenio

This page shows the latest Verzenio news and features for those working in and with pharma, biotech and healthcare.

NICE says no to Novartis’ Kisqali combo in breast cancer

NICE says no to Novartis’ Kisqali combo in breast cancer

It’s a blow to the company that is likely harder to take because a rival drug in the CDK 4/6 inhibitor class – Eli Lilly’s Verzenio (abemaciclib) – was backed ... Kisqali, Verzenio as well as Pfizer’s market-leading CDK 4/6 inhibitor Ibrance

Latest news

More from news
Approximately 6 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics